What's the forecast for the CSL share price in the second half of 2023?

The biotech giant has seen its stock go sideways since COVID-19 struck. Is it ready for a post-pandemic push upwards?

| More on:
Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Australian biotechnology giant CSL Limited (ASX: CSL) has made many investors wealthy over the decades, but it's been a struggle in recent times.

The brutal reality is that the share price is still 10% lower than its pre-COVID high.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

So has the healthcare stock passed its heyday, or are there brighter times ahead?

Let's take a look:

Poised for a break-out year

Morgans analysts reckon CSL shares are a buy, predicting a post-pandemic revival in the business and the stock price.

"We believe CSL is poised to break-out this year," they stated, according to The Motley Fool's James Mickelboro.

"A COVID-exit trade… offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares offering good value trading around its long-term forward multiple of ~30x."

The team has a handy 11.6% upside to the stock price over the next 12 months.

Another interesting endorsement is that CSL is currently the fifth most held stock among millionaires, according to investment platform Selfwealth Ltd (ASX: SWF).

"Our millionaire portfolio investors hold strong companies in strong sectors," said Selfwealth chief executive Cath Whitaker.

Big investors are bullish on CSL

Finally, there are plenty of institutional investors that are backing the biotech business.

The Motley Fool's Tristan Harrison reported this week that Australian Foundation Investment Co Ltd (ASX: AFI), Argo Investments Limited (ASX: ARG), and Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) all hold significant stakes in CSL.

"Argo and AFIC are two of the ASX's largest and oldest listed investment companies. They focus on ASX blue chip shares that can provide a mixture of dividends and capital growth," Harrison said.

"At the end of April, CSL shares were the third largest position in the AFIC portfolio, with an 8.1% weighting. CSL was also the third largest position in the Argo portfolio, with a 5.2% holding at the end of April."

The CSL share price is up 10.5% over the past year and 7.5% higher year to date.

Motley Fool contributor Tony Yoo has positions in CSL and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »